in this study, the eight ahr-active pharmaceuticals were investigated in highly aggressive aryl hydrocarbon (ah)-responsive bt474 and mda-mb-468 breast cancer cell lines, and their effects on ahr protein, cyp1a1 (protein and mrna), cyp1b1 (mrna), and cell migration were determined.